Skip to content


BMC Medical Ethics

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

  • David J. Pulford1Email author,
  • Philipp Harter2,
  • Anne Floquet3,
  • Catherine Barrett4,
  • Dong Hoon Suh5,
  • Michael Friedlander6,
  • José Angel Arranz7,
  • Kosei Hasegawa8,
  • Hiroomi Tada9, 22,
  • Peter Vuylsteke10,
  • Mansoor R. Mirza11,
  • Nicoletta Donadello12,
  • Giovanni Scambia13,
  • Toby Johnson1,
  • Charles Cox1,
  • John K. Chan14,
  • Martin Imhof15,
  • Thomas J. Herzog16,
  • Paula Calvert17,
  • Pauline Wimberger18,
  • Dominique Berton-Rigaud19,
  • Myong Cheol Lim20,
  • Gabriele Elser21,
  • Chun-Fang Xu1 and
  • Andreas du Bois2
BMC Medical EthicsBMC series – open, inclusive and trusted201617:63

Received: 15 January 2016

Accepted: 7 October 2016

Published: 21 October 2016

Back to article

Open Peer Review reports

Pre-publication versions of this article are available by contacting

Original Submission
15 Jan 2016 Submitted Original manuscript
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Resubmission - Version 4
Submitted Manuscript version 4
7 Oct 2016 Editorially accepted
21 Oct 2016 Article published 10.1186/s12910-016-0144-y

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting

You can find further information about the peer review system here.

Authors’ Affiliations

GlaxoSmithKline Medicines Research Centre, Stevenage, UK
AGO Study group and Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte (KEM), Essen, Germany
GINECO and Medical Oncology, Institut Bergonié, Bordeaux, France
GSK Stockley Park West, Uxbridge, UK
Department of Obstetrics & Gynecology, KGOG and Seoul National University Bundang Hospital, Seongnam-si, Korea
ANZGOG and The Prince of Wales Clinical School University of New South Wales, Randwick, Australia
GEICO and Hospital General Universitario Gregorio Marañón, Madrid, Spain
JGOG and Saitama Medical University International Medical Center, Hidaka, Japan
GlaxoSmithKline Research and Development, Philadelphia, USA
BGOG and Medical Oncology, Université Catholique de Louvain, CHU UCL Namur, Belgium
NSGO and Rigshospitalet, Copenhagen, Denmark
MaNGO and Ospedale Filippo del Ponte, Varese, Italy
Department of Woman Health, MITO and Catholic University of the Sacred Heart, Rome, Italy
Palo Alto Medical Foundation, San Francisco, USA
Karl Landsteiner Research Institute and Department of Obstetrics and Gynecology, General Public Teaching Hospital, Korneuburg, Vienna, Austria
NYGOG and University of Cincinnati Cancer Institute, Cincinnati, USA
Cancer Trials Ireland, Dublin 2, Ireland
AGO Germany and Department of Gynecology and Obstetrics, TU Dresden, Carl-Gustav-Carus University, Dresden, Germany
GINECO and ICO Centre René Gauducheau, Saint-Herblain, France
KGOG, Gynecologic Cancer Branch and Center for Uterine Cancer, National Cancer Center, Goyang, Korea
AGO Study Group, Wiesbaden, Germany
Immuno-Oncology Development, Incyte Corporation, Wilmington, USA